Even then, patients will not receive the treatments if insurers and governments refuse to pay. It is a real risk. For example, a different gene therapy for beta-thalassemia, developed by Bluebird Bio, was withdrawn from the European market after governments refused to pay the $1.8 million price tag. CRISPR 2.0 The first generation of CRISPR […]